Treatment of ovarian estrogen dependent conditions

Details Treatment of ovarian estrogen dependent conditions Treatment of ovarian estrogen dependent conditions

1994-02-04

1997-10-28

Tsang, Cecilia J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 91, 514 21, A61K 3800, A61K 3548, A61K 3824, C07K 1459

Patent

active

056818173

ABSTRACT:
A method of treating an ovarian estrogen dependent condition such as endometriosis, uterine leiomyomata, PMS or DUB involving the administration of gonadotropin releasing hormone analog and the administration of antiprogestin, which will provide a therapeutic method for long term treatment without rapid loss of bone density, as occurs using GnRH analogs alone.

REFERENCES:
Terakawa, N., "Studies on Endocrive Therapy for Endometriosis", Acta ohstet. Gynaecol. JPN (JPN ED) 41 (8) pp. 981-989 (1989). (Abstract).
Garzo et al., "Effects of antiprogesterone (RD486) . . . Cycle", J. Clin. Eud. Metah., 66(3), 508-17 (1988).
Carr et al., "An Evaluation . . . , Crossover Trial,", J. Clin. Endocrinology, vol. 76, No. 5, pp 1217-1223 (1993).

Affiliated with

Also associated with

Rating

Treatment of ovarian estrogen dependent conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of ovarian estrogen dependent conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of ovarian estrogen dependent conditions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1026151